03:20 , Aug 17, 2018 |  BC Week In Review  |  Company News

Almirall acquires U.S. dermatology products from Allergan

Almirall S.A. (Madrid:ALM) will acquire a portfolio of five dermatology products marketed in the U.S. from Allergan plc (NYSE:AGN) for $550 million in cash. The portfolio, which generated 1H18 sales of $70 million, includes acne and...
00:20 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Athenex's actinic keratosis ointment meets in pair of Phase III trials

Athenex Inc. (NASDAQ:ATNX) said KX2-391 (KX-01) met the primary endpoint of improving the proportion of patients who achieved complete clearance of actinic keratosis (AK) lesions within the face or scalp treatment areas at day 57...
22:56 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified p53-activating tetrahydroindazole-based DHODH inhibitors that could help treat melanoma. Screening of a small molecule library in human melanoma cell line-based assays of p53-dependent transcription, followed by chemical synthesis...
18:29 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Sun's IL-23 psoriasis mab approved by FDA

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya is a humanized mAb against IL-23 subunit alpha...
18:41 , Mar 21, 2018 |  BC Extra  |  Company News

Sun's IL-23 mAb gets FDA approval for psoriasis

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya is a humanized mAb against IL-23 subunit alpha...
18:14 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic lymphocytic leukemia (CLL) Patient sample, cell culture and mouse studies suggest inhibiting IL23P19-IL-23 receptor signaling could help treat CLL. In peripheral blood mononuclear cells (PBMCs) from patients, high levels of IL-23 receptor were...
23:03 , Jan 25, 2018 |  BC Extra  |  Financial News

Follow-on roundup: Audentes, Iovance

At least six companies have priced follow-ons since Wednesday’s market close, raising more than $600 million. Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $201.3 million after hours on Wednesday through the sale of 5.8...
21:46 , Dec 15, 2017 |  BC Week In Review  |  Company News

Athenex grants Almirall rights to KX2-391

Athenex Inc. (NASDAQ:ATNX) granted Almirall S.A. (Madrid:ALM) exclusive rights to develop and commercialize KX2-391 (KX-01) in the U.S. and parts of Europe, including Russia. Athenex will receive $55 million up front and is eligible for...
22:05 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Duaklir Genuair meets in Phase III to treat COPD

In September, AstraZeneca plc (LSE:AZN; NYSE:AZN) reported data from the Phase III AMPLIFY trial in about 1,595 patients with chronic obstructive pulmonary disease (COPD) showing that Duaklir Genuair aclidinium bromide/formoterol (Brimica, KRP-AB1102F, LAS40464) met the...
19:03 , Nov 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; musculoskeletal; neurology; renal

INDICATION: Multiple sclerosis (MS); tissue damage; ataxia; renal In vitro and cell culture studies identified a UBE2M-derived peptide inhibitor of the DCUND1-UBE2M interaction that could help treat NFE2L2-deficient diseases such MS, tissue damage, Friedreich’s ataxia and...